Replimune: 3 Key Takeaways for Long-Term Investors

Replimune successfully launched TUDRIQEV, its first commercial therapy for advanced melanoma, achieving rapid adoption with over 15 medical centers writing prescriptions within 20 business days. The company's in-house manufacturing facility provides over one year of ready inventory with next-day delivery capability nationwide. With $307.8 million in cash reserves, Replimune is well-positioned to fund operations and clinical studies for over 12 months, supported by major payer coverage and NCCN guideline listing.